Market Analysis and Insights: Global HER-2 Targeted Drugs for Breast Cancer Market
The research report studies the HER-2 Targeted Drugs for Breast Cancer market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global HER-2 Targeted Drugs for Breast Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global HER-2 Targeted Drugs for Breast Cancer Scope and Segment
The global HER-2 Targeted Drugs for Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HER-2 Targeted Drugs for Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Other
by Application, this report covers the following segments
Hospital
Clinic
Drug Center
Other
Global HER-2 Targeted Drugs for Breast Cancer market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The HER-2 Targeted Drugs for Breast Cancer key players in this market include:
Roche
Chugai Pharmaceutical
GlaxoSmithKline
Novartis
Pfizer
CANbridge
Puma Biotechnology
Hengrui Medicine
Beacon Pharmaceuticals Limited
Hetero Drugs
The research report studies the HER-2 Targeted Drugs for Breast Cancer market using different methodologies and analyzes to provide accurate and in-depth information about the market. For a clearer understanding, it is divided into several parts to cover different aspects of the market. Each area is then elaborated to help the reader comprehend the growth potential of each region and its contribution to the global market. The researchers have used primary and secondary methodologies to collate the information in the report. They have also used the same data to generate the current market scenario. This report is aimed at guiding people towards an apprehensive, better, and clearer knowledge of the market.
The global HER-2 Targeted Drugs for Breast Cancer market size is projected to reach US$ XX million by 2026, from US$ XX million in 2020, at a CAGR of XX% during 2021-2026.
Global HER-2 Targeted Drugs for Breast Cancer Scope and Segment
The global HER-2 Targeted Drugs for Breast Cancer market is segmented by company, region (country), by Type, and by Application. Players, stakeholders, and other participants in the global HER-2 Targeted Drugs for Breast Cancer market will be able to gain the upper hand as they use the report as a powerful resource. The segmental analysis focuses on revenue and forecast by region (country), by Type, and by Application for the period 2015-2026.
by Type, the market is primarily split into
Trastuzumab
Pertuzumab
Lapatinib
Neratinib
Trastuzumab Emtansine
Pyrotinib
Other
by Application, this report covers the following segments
Hospital
Clinic
Drug Center
Other
Global HER-2 Targeted Drugs for Breast Cancer market: regional analysis, the major regions covered in the report are:
North America
United States
Canada
Europe
Germany
France
U.K.
Italy
Russia
Nordic
Rest of Europe
Asia-Pacific
China
Japan
South Korea
Southeast Asia
India
Australia
Rest of Asia-Pacific
Latin America
Mexico
Brazil
Middle East & Africa
Turkey
Saudi Arabia
UAE
Rest of Middle East & Africa
The report lists the major players in the regions and their respective market share on the basis of global revenue. It also explains their strategic moves in the past few years, investments in product innovation, and changes in leadership to stay ahead in the competition. This will give the reader an edge over others as a well-informed decision can be made looking at the holistic picture of the market.
The HER-2 Targeted Drugs for Breast Cancer key players in this market include:
Roche
Chugai Pharmaceutical
GlaxoSmithKline
Novartis
Pfizer
CANbridge
Puma Biotechnology
Hengrui Medicine
Beacon Pharmaceuticals Limited
Hetero Drugs
1 Market Overview of HER-2 Targeted Drugs for Breast Cancer
1.1 HER-2 Targeted Drugs for Breast Cancer Market Overview
1.1.1 HER-2 Targeted Drugs for Breast Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2015-2026)
1.4 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2015-2020)
1.5 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Region (2021-2026)
1.6 Key Regions, HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.4 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
2 HER-2 Targeted Drugs for Breast Cancer Market Overview by Type
2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)
2.3 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)
2.4 Trastuzumab
2.5 Pertuzumab
2.6 Lapatinib
2.7 Neratinib
2.8 Trastuzumab Emtansine
2.9 Pyrotinib
2.10 Other
3 HER-2 Targeted Drugs for Breast Cancer Market Overview by Application
3.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Application (2015-2020)
3.3 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Drug Center
3.7 Other
4 Global HER-2 Targeted Drugs for Breast Cancer Competition Analysis by Players
4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2019)
4.3 Date of Key Manufacturers Enter into HER-2 Targeted Drugs for Breast Cancer Market
4.4 Global Top Players HER-2 Targeted Drugs for Breast Cancer Headquarters and Area Served
4.5 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 HER-2 Targeted Drugs for Breast Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.1.4 Roche HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.1.5 Roche Recent Developments
5.2 Chugai Pharmaceutical
5.2.1 Chugai Pharmaceutical Profile
5.2.2 Chugai Pharmaceutical Main Business
5.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.2.4 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.2.5 Chugai Pharmaceutical Recent Developments
5.3 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.3.2 GlaxoSmithKline Main Business
5.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.3.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.4.4 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.4.5 Novartis Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.5.4 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.5.5 Pfizer Recent Developments
5.6 CANbridge
5.6.1 CANbridge Profile
5.6.2 CANbridge Main Business
5.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.6.4 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.6.5 CANbridge Recent Developments
5.7 Puma Biotechnology
5.7.1 Puma Biotechnology Profile
5.7.2 Puma Biotechnology Main Business
5.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.7.4 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.7.5 Puma Biotechnology Recent Developments
5.8 Hengrui Medicine
5.8.1 Hengrui Medicine Profile
5.8.2 Hengrui Medicine Main Business
5.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.8.4 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.8.5 Hengrui Medicine Recent Developments
5.9 Beacon Pharmaceuticals Limited
5.9.1 Beacon Pharmaceuticals Limited Profile
5.9.2 Beacon Pharmaceuticals Limited Main Business
5.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.9.4 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.9.5 Beacon Pharmaceuticals Limited Recent Developments
5.10 Hetero Drugs
5.10.1 Hetero Drugs Profile
5.10.2 Hetero Drugs Main Business
5.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.10.4 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.10.5 Hetero Drugs Recent Developments
6 North America
6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 HER-2 Targeted Drugs for Breast Cancer Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
1.1 HER-2 Targeted Drugs for Breast Cancer Market Overview
1.1.1 HER-2 Targeted Drugs for Breast Cancer Product Scope
1.1.2 Market Status and Outlook
1.2 Global HER-2 Targeted Drugs for Breast Cancer Market Size Overview by Region 2015 VS 2020 VS 2026
1.3 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Region (2015-2026)
1.4 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Region (2015-2020)
1.5 Global HER-2 Targeted Drugs for Breast Cancer Market Size Forecast by Region (2021-2026)
1.6 Key Regions, HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.2 Europe HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.3 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.4 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
1.6.5 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size YoY Growth (2015-2026)
2 HER-2 Targeted Drugs for Breast Cancer Market Overview by Type
2.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Type: 2015 VS 2020 VS 2026
2.2 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Type (2015-2020)
2.3 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Type (2021-2026)
2.4 Trastuzumab
2.5 Pertuzumab
2.6 Lapatinib
2.7 Neratinib
2.8 Trastuzumab Emtansine
2.9 Pyrotinib
2.10 Other
3 HER-2 Targeted Drugs for Breast Cancer Market Overview by Application
3.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Application: 2015 VS 2020 VS 2026
3.2 Global HER-2 Targeted Drugs for Breast Cancer Historic Market Size by Application (2015-2020)
3.3 Global HER-2 Targeted Drugs for Breast Cancer Forecasted Market Size by Application (2021-2026)
3.4 Hospital
3.5 Clinic
3.6 Drug Center
3.7 Other
4 Global HER-2 Targeted Drugs for Breast Cancer Competition Analysis by Players
4.1 Global HER-2 Targeted Drugs for Breast Cancer Market Size by Players (2015-2020)
4.2 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in HER-2 Targeted Drugs for Breast Cancer as of 2019)
4.3 Date of Key Manufacturers Enter into HER-2 Targeted Drugs for Breast Cancer Market
4.4 Global Top Players HER-2 Targeted Drugs for Breast Cancer Headquarters and Area Served
4.5 Key Players HER-2 Targeted Drugs for Breast Cancer Product Solution and Service
4.6 Competitive Status
4.6.1 HER-2 Targeted Drugs for Breast Cancer Market Concentration Rate
4.6.2 Mergers & Acquisitions, Expansion Plans
5 Company (Top Players) Profiles and Key Data
5.1 Roche
5.1.1 Roche Profile
5.1.2 Roche Main Business
5.1.3 Roche HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.1.4 Roche HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.1.5 Roche Recent Developments
5.2 Chugai Pharmaceutical
5.2.1 Chugai Pharmaceutical Profile
5.2.2 Chugai Pharmaceutical Main Business
5.2.3 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.2.4 Chugai Pharmaceutical HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.2.5 Chugai Pharmaceutical Recent Developments
5.3 GlaxoSmithKline
5.5.1 GlaxoSmithKline Profile
5.3.2 GlaxoSmithKline Main Business
5.3.3 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.3.4 GlaxoSmithKline HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.3.5 Novartis Recent Developments
5.4 Novartis
5.4.1 Novartis Profile
5.4.2 Novartis Main Business
5.4.3 Novartis HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.4.4 Novartis HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.4.5 Novartis Recent Developments
5.5 Pfizer
5.5.1 Pfizer Profile
5.5.2 Pfizer Main Business
5.5.3 Pfizer HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.5.4 Pfizer HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.5.5 Pfizer Recent Developments
5.6 CANbridge
5.6.1 CANbridge Profile
5.6.2 CANbridge Main Business
5.6.3 CANbridge HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.6.4 CANbridge HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.6.5 CANbridge Recent Developments
5.7 Puma Biotechnology
5.7.1 Puma Biotechnology Profile
5.7.2 Puma Biotechnology Main Business
5.7.3 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.7.4 Puma Biotechnology HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.7.5 Puma Biotechnology Recent Developments
5.8 Hengrui Medicine
5.8.1 Hengrui Medicine Profile
5.8.2 Hengrui Medicine Main Business
5.8.3 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.8.4 Hengrui Medicine HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.8.5 Hengrui Medicine Recent Developments
5.9 Beacon Pharmaceuticals Limited
5.9.1 Beacon Pharmaceuticals Limited Profile
5.9.2 Beacon Pharmaceuticals Limited Main Business
5.9.3 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.9.4 Beacon Pharmaceuticals Limited HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.9.5 Beacon Pharmaceuticals Limited Recent Developments
5.10 Hetero Drugs
5.10.1 Hetero Drugs Profile
5.10.2 Hetero Drugs Main Business
5.10.3 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Products, Services and Solutions
5.10.4 Hetero Drugs HER-2 Targeted Drugs for Breast Cancer Revenue (US$ Million) & (2015-2020)
5.10.5 Hetero Drugs Recent Developments
6 North America
6.1 North America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
6.2 United States
6.3 Canada
7 Europe
7.1 Europe HER-2 Targeted Drugs for Breast Cancer Market Size by Country
7.2 Germany
7.3 France
7.4 U.K.
7.5 Italy
7.6 Russia
7.7 Nordic
7.8 Rest of Europe
8 Asia-Pacific
8.1 Asia-Pacific HER-2 Targeted Drugs for Breast Cancer Market Size by Region
8.2 China
8.3 Japan
8.4 South Korea
8.5 Southeast Asia
8.6 India
8.7 Australia
8.8 Rest of Asia-Pacific
9 Latin America
9.1 Latin America HER-2 Targeted Drugs for Breast Cancer Market Size by Country
9.2 Mexico
9.3 Brazil
9.4 Rest of Latin America
10 Middle East & Africa
10.1 Middle East & Africa HER-2 Targeted Drugs for Breast Cancer Market Size by Country
10.2 Turkey
10.3 Saudi Arabia
10.4 UAE
10.5 Rest of Middle East & Africa
11 HER-2 Targeted Drugs for Breast Cancer Market Dynamics
11.1 Industry Trends
11.2 Market Drivers
11.3 Market Challenges
11.4 Market Restraints
12 Research Finding /Conclusion
13 Methodology and Data Source
13.1 Methodology/Research Approach
13.1.1 Research Programs/Design
13.1.2 Market Size Estimation
13.1.3 Market Breakdown and Data Triangulation
13.2 Data Source
13.2.1 Secondary Sources
13.2.2 Primary Sources
13.3 Disclaimer
13.4 Author List
